AI Engines For more Details: Perplexity Kagi Labs You
Appetite Suppression: Phentermine hydrochloride is a sympathomimetic amine that works by stimulating the release of neurotransmitters such as norepinephrine, which suppress appetite and increase feelings of fullness. This effect can help individuals consume fewer calories and achieve weight loss.
Weight Loss: Phentermine hydrochloride is indicated for short-term use (usually a few weeks) as an adjunct to lifestyle interventions for the management of obesity. It can lead to modest weight loss when combined with dietary changes and increased physical activity.
Increased Energy Expenditure: By stimulating the release of norepinephrine, phentermine hydrochloride can also increase energy expenditure, potentially contributing to weight loss.
Cardiovascular Effects: Phentermine hydrochloride may cause increases in heart rate and blood pressure due to its sympathomimetic effects. Individuals with pre-existing cardiovascular conditions or hypertension may be at increased risk of adverse cardiovascular effects and should be monitored closely.
Central Nervous System Effects: Common side effects of phentermine hydrochloride may include insomnia, restlessness, nervousness, anxiety, and irritability. These effects are often related to its stimulant properties and may decrease with continued use.
Gastrointestinal Effects: Phentermine hydrochloride may cause dry mouth, constipation, or diarrhea in some individuals. These effects are usually mild and transient.
Psychiatric Effects: Rarely, phentermine hydrochloride may exacerbate pre-existing psychiatric conditions such as depression or bipolar disorder, leading to mood changes or worsening of symptoms. Patients should be monitored for changes in mood or behavior during treatment.
Tolerance and Dependence: Phentermine hydrochloride has the potential for tolerance and dependence, particularly with long-term use or misuse. Abrupt discontinuation after prolonged use may result in withdrawal symptoms such as fatigue, depression, and changes in sleep patterns.
Drug Interactions: Phentermine hydrochloride may interact with other medications, particularly monoamine oxidase inhibitors (MAOIs) and other drugs that affect serotonin levels, increasing the risk of serotonin syndrome. It may also interact with other sympathomimetic medications, increasing the risk of cardiovascular side effects.
Pulmonary Hypertension: Rare cases of pulmonary hypertension (high blood pressure in the arteries of the lungs) have been reported with the use of phentermine hydrochloride, particularly with long-term use. Patients should be monitored for signs and symptoms of pulmonary hypertension, such as shortness of breath, chest pain, or fainting.
Contraindications: Phentermine hydrochloride is contraindicated in individuals with a history of cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or a known hypersensitivity to sympathomimetic amines. It is also not recommended for use during pregnancy or breastfeeding.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.8 | 0.8 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.6 | 0.6 | |
| Allergy to milk products | 0.3 | 0.3 | |
| Alzheimer's disease | 1 | 1 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.6 | |
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Anorexia Nervosa | 0.4 | -0.4 | |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 0.4 | -0.4 | |
| Atherosclerosis | 0.2 | -0.2 | |
| Atrial fibrillation | 0.3 | 0.3 | 0 |
| Autism | 0.4 | 1 | -1.5 |
| Bipolar Disorder | 0.3 | 0.1 | 2 |
| Brain Trauma | 0.4 | -0.4 | |
| Carcinoma | 0.3 | 0.3 | 0 |
| Celiac Disease | 0.3 | 0.3 | 0 |
| Cerebral Palsy | 0.4 | -0.4 | |
| Chronic Fatigue Syndrome | 1.2 | 0.3 | 3 |
| Chronic Kidney Disease | 0.3 | 0.1 | 2 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | -0.1 | |
| Chronic Urticaria (Hives) | 0.6 | -0.6 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Colorectal Cancer | 1 | 1 | |
| Constipation | 0.3 | 0.1 | 2 |
| COVID-19 | 1.1 | 1.3 | -0.18 |
| Crohn's Disease | 1.8 | 1 | 0.8 |
| cystic fibrosis | 0.4 | -0.4 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 2.1 | 0.4 | 4.25 |
| Eczema | 0.6 | -0.6 | |
| Endometriosis | 0.3 | 0.3 | |
| Epilepsy | 1 | 0.3 | 2.33 |
| Fibromyalgia | 0.1 | 1.1 | -10 |
| Functional constipation / chronic idiopathic constipation | 1.1 | 1 | 0.1 |
| gallstone disease (gsd) | 0.1 | -0.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.6 | |
| Generalized anxiety disorder | 0.3 | -0.3 | |
| Graves' disease | 0.3 | 0.1 | 2 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.4 | 0.3 | 0.33 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0.4 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 1 | -2.33 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.7 | -0.7 | |
| Inflammatory Bowel Disease | 1 | 1.2 | -0.2 |
| Insomnia | 0.3 | 0.4 | -0.33 |
| Intelligence | 0.7 | 0.7 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.4 | 1.2 | -2 |
| Liver Cirrhosis | 0.4 | 0.4 | 0 |
| Long COVID | 0.3 | 0.4 | -0.33 |
| Low bone mineral density | 0.1 | -0.1 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.1 | 0.3 | -2 |
| Metabolic Syndrome | 1 | 1.8 | -0.8 |
| Mood Disorders | 2.1 | 0.4 | 4.25 |
| Multiple Sclerosis | 1 | -1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | -0.3 | |
| Obesity | 0.4 | 0.3 | 0.33 |
| obsessive-compulsive disorder | 1.7 | 0.3 | 4.67 |
| Osteoarthritis | 0.3 | 0.3 | |
| Osteoporosis | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 0.8 | -0.8 | |
| Polycystic ovary syndrome | 0.3 | 0.1 | 2 |
| primary biliary cholangitis | 0.7 | -0.7 | |
| Psoriasis | 0.6 | 0.4 | 0.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 1 | -1.5 |
| Rosacea | 0.1 | -0.1 | |
| Schizophrenia | 1.1 | 0.1 | 10 |
| Sjögren syndrome | 1.1 | -1.1 | |
| Sleep Apnea | 0.4 | -0.4 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.4 | 0 |
| Systemic Lupus Erythematosus | 1 | 0.1 | 9 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1 | 0.1 | 9 |
| Type 2 Diabetes | 1 | 1.8 | -0.8 |
| Ulcerative colitis | 0.3 | 1.2 | -3 |
| Unhealthy Ageing | 1 | 0.1 | 9 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.